Conflict of interest: P.G. Middleton reports grants from HCF Australia and the Canadian Institutes of Health, consultancy fees from Vertex Pharma, payment or honoraria for lectures, presentations, manuscript writing or educational events from Vertex Pharma, AstraZeneca and Limbic, payment for expert testimony from Shine Lawyers, support for attending meetings from NSW Health, participation on a data safety monitoring board or advisory board with Cystic Fibrosis Foundation, is a member of a steering committee for the Australian Bronchiectasis Registry, Australian CF Data Registry, the Australian CF Standards of Care Committee and the ECFS Standards of Care Committee, and has stock (or stock options) with Resmed Inc. and Sanofi Pharma. N.J. Simmonds reports grants from Vertex (Innovation Grant), consultancy fees from Vertex Pharma, payment or honoraria for lectures, presentations, manuscript writing or educational events from Vertex Pharma, Chiesi, Gilead and Menarini, support for attending meetings from Vertex Pharma, participation on a data safety monitoring board or advisory board with Vertex and Chiesi, and is Deputy Director and Protocol Chair for the ECFS Clinical Trials Network, coordinator for the ECFS Diagnostic Network Working Group and chair of the UK CF Trust Registry Research Committee.